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RESEARCH ARTICLE
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Acute kidney injury (AKI) is a highly morbid condition in critically ill patients that is associated with high mortality. Previous clinical studies have demonstrated the safety and efficacy
of the Selective Cytopheretic Device (SCD) in the treatment of AKI requiring continuous
renal replacement therapy in the intensive care unit (ICU).
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Design, Setting, Patients
A randomized, controlled trial of 134 ICU patients with AKI, 69 received continuous renal
replacement therapy (CRRT) alone and 65 received SCD therapy.

Results
No significant difference in 60-day mortality was observed between the treated (27/69; 39%)
and control patients (21/59; 36%, with six patients lost to follow up) in the intention to treat
(ITT) analysis. Of the 19 SCD subjects (CRRT+SCD) and 31 control subjects (CRRT alone)
who maintained a post-filter ionized calcium (iCa) level in the protocol’s recommended range
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( 0.4mmol/L) for greater or equal to 90% of the therapy time, 60-day mortality was 16% (3/
19) in the SCD group compared to 41% (11/27) in the CRRT alone group (p = 0.11). Dialysis
dependency showed a borderline statistically significant difference between the SCD treated
versus control CRRT alone patients maintained for  90% of the treatment in the protocol’s
recommended (r) iCa target range of  0.4 mmol/L with values of, 0% (0/16) and 25% (4/16),
respectively (P = 0.10). When the riCa treated and control subgroups were compared for a
composite index of 60 day mortality and dialysis dependency, the percentage of SCD treated
subjects was 16% versus 58% in the control subjects (p<0.01). The incidence of serious
adverse events did not differ between the treated (45/69; 65%) and control groups (40/65;
63%; p = 086).

Conclusion
SCD therapy may improve mortality and reduce dialysis dependency in a tightly controlled
regional hypocalcaemic environment in the perfusion circuit.

Trial Registration
ClinicalTrials.gov NCT01400893 http://clinicaltrials.gov/ct2/show/NCT01400893

Introduction
Acute kidney injury (AKI) is a highly morbid condition in critically ill patients with mortality
rates exceeding 50% [1–5]. Although dialysis removes waste products and corrects fluid
imbalance, it does not perform the absorptive, metabolic, endocrine, and immunologic functions of normal renal tubule cells. As a result, AKI promotes a systemic inflammatory response
syndrome (SIRS) which results in systemic microvascular damage and, if severe, multi-organ
dysfunction [6, 7]. Activated circulating leukocytes play a central role in this process [8]. Leukocytes, especially neutrophils, are major contributors to the pathogenesis and progression of
many inflammatory disorders, including SIRS, sepsis, ischemia reperfusion injury, and acute
respiratory distress syndrome (ARDS). Many therapeutic approaches are under investigation
to limit the activation and tissue accumulation of leukocytes at sites of inflammation to minimize tissue destruction and disease progression [9–11].
The Selective Cytopheretic Device (SCD) is comprised of tubing, connectors, and a synthetic membrane cartridge that binds and deactivates leukocytes which are activated from an
inflammatory process, and, when used in a continuous renal replacement extracorporeal circuit in the presence of regional citrate anticoagulation (RCA), modulates inflammation [12].
Previous clinical studies have demonstrated the safety and efficacy of the SCD in the treatment
of AKI requiring continuous renal replacement therapy (CRRT) in the intensive care unit
(ICU). In a Phase-IIa, prospective, single-arm, single-center study designed to evaluate the
safety and device integrity of treatment with the SCD [13], 12 patients enrolled in the trial were
compared with historical case-matched controls with respect to age and Sequential Organ Failure Assessment (SOFA) score. The mortality for the case-matched controls was 78%, whereas
the mortality in the SCD treatment group was 22% (p = 003). Multivariate regression analysis
identified treatment with SCD as the only significant variable affecting mortality. Mean total
urine output in the 10 subjects receiving SCD treatment increased from a baseline of approximately 500 ml/d to more than 2,000 ml/d by day seven of treatment. No serious device related
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adverse events were reported. In a Phase-IIb, prospective, single-arm, multicenter US pilot
study designed to evaluate the safety and efficacy of the SCD treatment on AKI requiring
CRRT in the ICU [14]. The study enrolled 35 subjects. The average SOFA score of the patients
was
113 ± 36. Death from any cause at Day 60 was 314%. Renal recovery, defined as dialysis
independence, was observed in all of the surviving subjects at Day 60. The results of this pilot
study indicated the potential for a substantial improvement in patient outcomes over standard
of care therapy (CRRT alone), and prompted the design of the Phase IIIa trial described herein.
The primary objective of this study was to determine whether CRRT + SCD treatment, compared to CRRT alone, results in significantly improved all-cause mortality through Day 60. Secondary objectives included an assessment of renal replacement therapy (RRT) dependency at
Day 60, mortality at Day 28, the number of ventilator free days (VFD) at Day 28, and the mortality of the subset of patients with severe sepsis at Day 60.

Materials and Methods
This was a two-arm, randomized, open-label, controlled multi-center study and was performed
under an FDA-approved investigational device exemption (IDE# G090189). This study and
the clinical protocol are accessible at clinicaltrial.gov, ID# NCT 01400893. Each enrolling site
had IRB approval to undertake this clinical investigation. The institutional review boards
named below specifically approved this study, and all participants involved in the study signed
informed consent.

Center Name / IRB Type
University of Texas/Local, University of Wisconsin/Central WIRB (Western Institutional
Review Board), University of Maryland/Local, Massachusetts General/Local, U of California
Los Angeles/Local, Mount Sinai/Local, SERRI (Memorial)/Central WIRB, SERRI (Erlanger)/
Local, Cleveland Clinic/Local, Northwestern University/Local, U of California San Diego
(UCSD)/Local, U of Florida (Jacksonville)/Central WIRB, Virginia Commonwealth/Central
WIRB, Medical U of S Carolina/Central WIRB, Beth Israel Deaconess/Local, U of Florida
(Gainesville)/Central WIRB, University of Arizona/Central WIRB, Dallas VA/Local, Henry
Ford Health System/Local, VA Medical Center Buffalo/Local, Washington University/Local,
University of Mississippi/Local, U of Alabama Birmingham/Central IRB, INOVA Fairfax/
Central WIRB, University of Iowa/Central WIRB, Albany Medical College/Central WIRB,
(WNERTA) Western N England Renal and Transplant Associates /Local.
134 subjects were enrolled in 21 US medical centers. Patients receiving care in the ICU
of each participating hospital were randomized to intensive care treatment for patients
undergoing CRRT or CRRT + SCD. Any mode of CRRT was allowed (CVVH, CVVHD, and
CVVHDF) following each participating clinical site’s protocol, with minimal effluent rate (dialysate and ultrafiltrate) of at least 25ml/Kg/h. The modality of CRRT was not expected to affect
performance of the SCD. All CRRT was delivered via one pre-specified dialysis pump system
(B. Braun Diapact CRRT System), and was supplied by CytoPherx, Inc. (Ann Arbor, MI)
Each participating clinical site used their established regional citrate anticoagulation
(RCA) protocol for the CRRT and SCD circuits (Study Arm) and for the CRRT only (Control
Arm). The recommended ionized calcium level (measured post SCD-ARF) in the CRRT and
SCD-ARF blood circuit was specified to be between 025 and 04 mmol/L. Inclusion and exclusion criteria are described in Tables 1 and 2.
A centralized randomization system was established with 24-hour availability to provide a
mechanism to randomize subjects and enroll them in the study. Once the patient met all
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Table 1. Inclusion criteria.
1.

A patient, or legal representative, has signed a written informed consent form.

2.

Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma).

3.

Age 18 to 80 years.

4.

Females of child bearing potential who are not pregnant (conﬁrmed by a negative serum pregnancy
test) and not lactating if recently post-partum.

5.

Must be receiving and tolerating CRRT therapy for a minimum of 4 hours, but not longer than 24.

6.

Expected to remain in the ICU for at least 96 hours after evaluation for enrollment.

7.

A clinical diagnosis of ATN due to hemodynamic or toxic etiologies. ATN is deﬁned as Acute Kidney
Injury occurring in a setting of acute ischemic or nephrotoxic injury with oliguria (average <20 mL/hr)
for >6–12 hours or: an increase in serum creatinine 2 mg/dL (1.5 mg/dL in females) over a period
of 4 days. (Note: Prerenal, hepatorenal, vascular, interstitial, glomerular, and obstructive etiologies
are excluded on clinical or other diagnostic grounds.)

8.

At least one non-renal organ failure (SOFA organ system score 2) or presence (proven or suspected)
of sepsis.

9.

All patients must be able to tolerate regional citrate anticoagulation.

doi:10.1371/journal.pone.0132482.t001

eligibility criteria, including being on CRRT for a minimum of four hours, but no longer than
24 hours, and had signed informed consent, the subject was randomized in a 1:1 allocation
Table 2. Exclusion Criteria.
1.

Irreversible brain damage based on available historical and clinical information.

2.

Presence of a renal transplant at any time.

3.

Non-renal organ transplantation within six month of screening.

4.

Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring chronic renal
replacement therapy prior to this episode of acute kidney injury.

5.

AKI occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or
rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome, thrombotic
thrombocytopenic purpura (TTP), malignant hypertension, scleroderma renal crisis, atheroembolism,
functional or surgical nephrectomy, hepatorenal syndrome, cyclosporine or tacrolimus nephrotoxicity.

6.

Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation
during the subsequent three month period after study therapy.

7.

Chronic immunosuppression (e.g., HIV/AIDS, chronic glucocorticoid therapy >20 mg/day prednisone
equivalent on a chronic basis). The acute use of glucocorticoids is permissible.

8.

Severe liver failure as documented by a Child-Pugh Liver Failure Score >12 (see Appendix F).

9.

Do Not Resuscitate Status (DNR).

10.

Comfort measures only

11.

Patient is moribund or for whom full supportive care is not indicated.

12.

Patient is not expected to survive 28 days because of an irreversible medical condition. (This is not
restrictive to AKI, and may include situations such as the presence of irreversible brain damage,
untreatable malignancy, inoperable life threatening condition, or any condition to which therapy is
regarded as futile by the PI.)

13.

Any medical condition that the Investigator thinks may interfere with the study objectives.

14.

Physician refusal.

15.

Patient is a prisoner.

16.

Dry weight of >150 kg.

17.

More than one hemodialysis treatment during this hospital admission or prior to transfer from an
outside hospital.

18.

Platelet count <30,000/mm3

19.

Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where
only measurements and/or samples are taken (NO TEST DEVICE OR TEST DRUG USED) are
allowed to participate.

20.

Use of any other Investigational drug or device within the previous 30 days.

doi:10.1371/journal.pone.0132482.t002
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Fig 1. Flow chart of the disposition in all of the patients (N = 134) enrolled. For the purpose of statistical
analysis ITT is defined as all control and all treatment, whereas mITT is defined as all control and all
treatment with iCa at recommended range >90% of the time.
doi:10.1371/journal.pone.0132482.g001

utilizing a random permuted block design into either the control or treatment arm, stratified
by study center and the presence of severe sepsis.
Patients randomized to the control arm received renal replacement therapy utilizing a
CRRT pump system that is identical to that used for the SCD treatment, tubing and hemofilter
provided by the sponsor (CytoPherx, Inc., Ann Arbor, MI). Anticoagulation of the system was
accomplished using the institution’s protocol for citrate anticoagulation with a target range
for intra-circuit ionized calcium of 025–040 mmol/L. All patients in the control arm were
required to use citrate as an anticoagulant. Patients randomized to the study treatment arm
received renal replacement therapy identical to the control arm, plus the SCD (Fig 1). The SCD
was placed in the CRRT blood circuit as detailed (S1 Fig).
An overall two-sided 005 level of significance at 80% power was used to calculate a sample
size of 344 patients, assuming a mortality rate of 50% for control and 35% for the treatment
groups [1–5]. An interim analysis for sample size re-estimation was planned at the mid-point
of enrollment (172 subjects).
The primary outcome was all-cause mortality through Day 60. Secondary outcomes
included an assessment of renal replacement therapy (RRT) dependency at Day 60, mortality
at Day 28, the number of ventilator free days (VFD) at Day 28, and the mortality of the subset
of patients with severe sepsis at Day 60. Several exploratory biomarkers were also compared
between the control and treatment groups, including urine output, serum levels of elastase,
IL-6, and IL-10, and total absolute white blood cell, neutrophil, and platelet counts throughout
treatment.
Fisher exact tests were used to compare the primary and outcomes, and chi-square tests
were used for the occurrence of adverse events across randomized treatment groups for the
intention to treat (ITT) population as well as the modified intention to treat (mITT) population. ITT was defined as all control and all treatment, whereas mITT is defined as all control
and all treatment with iCa at recommended range >90% of the time. Kaplan-Meier curves
and log-rank tests were used to compare the time to mortality across treatment groups. Differences between treatment groups in continuous outcomes (e.g., urine output, white blood cell
count, number of neutrophils, elastase) over time were assessed with repeated measures linear
regression models, including an interaction term to estimate the difference in change over time
(i.e. slope) between groups. These models excluded the baseline (i.e., pre-treatment) values.
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Statistical analyses were performed with Stata/MP 121 (www.stata.com). Two-sided p-values
of <005 were considered statistically significant.

Results
The trial was initiated on September 8, 2011. During the second quarter of the enrollment
period, a national calcium shortage occurred in the US. Due to the reliance of the SCD on a
narrow intra-circuit ionized calcium range for it to function effectively and the concern that
patients randomized to the SCD were not getting effective therapy, the interim analysis was
performed early—after enrollment of 134 patients. Enrollment was paused on May 24, 2013, to
assess the clinical impact of the calcium shortage on study endpoints. The shortage of calcium
infusion solutions resulted in a tendency to minimize citrate infusion rates. Accordingly, the
ionized calcium levels within the blood circuit tended to be above the recommended range of
025 to 040 mmol/L in the majority of the subjects. The study was terminated by the sponsor
at the interim analysis because the SCD treatment was often outside the recommended iCa
range, and therefore, resulted in ineffective therapy.
No significant differences were noted between the ITT or mITT control and treatment
groups in terms of baseline characteristics Table 3. Of the 134 patients in the analysis, 69
received CRRT alone and 65 received SCD therapy (S1 Fig). The days on CRRT were similar
in both groups with control and treatment groups averaging 5.4 ± 2.4 and 5.2 ± 2.1 days,
respectively. No statistically significant difference was found between the treated and control
patients of the ITT population, with a 60 day mortality of 39% (27/69) and 36% (21/59) respectively, with six patients in the control group lost to follow up, Table 4, (S2 Fig) (log-rank pvalue = 0.23).
The hazard ratio for mortality within the first 60 days associated with treatment was 1.32
(95% confidence interval [CI]: 0.74, 2.35).
There were no statistically significant differences in the secondary endpoints (RRT dependency at Day 60, mortality at Day 28, VFD at Day 28, and the mortality of the subset of
patients with severe sepsis at Day 60) between the treatment and control group of the ITT population. Table 5 delineates the summary of site-reported serious adverse events (SAEs) using
site-reported category and term for the ITT population. No statistically significant difference
was found between the SAEs of the control and treatment groups. Furthermore, none of the
SAEs were considered ‘definitely’ device related per the principal investigator. Overall adverse
events did not differ between the treatment and control groups in the ITT analysis.
The amount of time the subjects in both the control and treatment group were maintained
in the recommended ionized calcium range (025–040 mmol/L), as specified in the study
protocol, was substantially lower than expected. Of the 134 subjects enrolled in the SCD-003
protocol at the time of the interim analysis, 19 SCD subjects (CRRT+SCD) and 31 control subjects (CRRT alone) were maintained in the protocol’s recommended range ( 04mmol/L) for
greater or equal to 90% of the therapy time. Table 6 and (S3 Fig) (log-rank p-value = 0.27)
describe the mortality at Day 60 (primary endpoint) of the treated subjects which received the
recommended ionized calcium (riCa). Mortality in this subset was 16% (3/19) in the SCD
group compared to 41% (11/27) in the CRRT alone group, (pexact = 011). The hazard ratio for
mortality within 60 days for this subset was 0.46 (95% CI: 0.13, 1.65). This subset of subjects
did not differ significantly in terms of age, gender, race, presence of sepsis, or mean SOFA
score (Table 7) and did not differ in baseline characteristics from the non-riCa
The secondary endpoints of renal replacement therapy dependency at Day 60, mortality at
Day 28, number of ventilator free days at Day 28 and mortality of the sub population of severe
septic patients at Day 60 were analyzed. No statistical significance was shown except for the
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Table 3. Demographics of All Study Subjects.

Age (years)

CRRT + SCD

CRRT Alone

Overall

N = 69

N = 65

N = 134

57.2 ± 13.1 (69)

53.5 ± 14.7 (65)

55.4 ± 14.0 (134)

Sex
Male

60.9% (42/69)

61.5% (40/65)

61.2% (82/134)

Female

39.1% (27/69)

38.5% (25/65)

38.8% (52/134)

Hispanic or Latino

4.3% (3/69)

3.1% (2/65)

3.7% (5/134)

Non-Hispanic or Latino

89.9% (62/69)

86.2% (56/65)

88.1% (118/134)

Unknown

5.8% (4/69)

10.8% (7/65)

8.2% (11/134)

Ethnicity

Race
American Indian or Alaska Native

0.0% (0/69)

0.0% (0/65)

0.0% (0/134)

Asian

0.0% (0/69)

0.0% (0/65)

0.0% (0/134)

Black/African American

21.7% (15/69)

21.5% (14/65)

21.6% (29/134)

Native Hawaiian or Other Paciﬁc Islander

0.0% (0/69)

0.0% (0/65)

0.0% (0/134)

White/Caucasian

76.8% (53/69)

73.8% (48/65)

75.4% (101/134)

Unknown

0.0% (0/69)

1.5% (1/65)

0.7% (1/134)

Other

1.4% (1/69)

3.1% (2/65)

2.2% (3/134)

Body Weight (kg)

102.0 ± 23.1 (62)

98.8 ± 23.6 (56)

100.5 ± 23.3 (118)

SOFA Score

13.8 ± 3.2 (67)

13.2 ± 3.7 (64)

13.5 ± 3.4 (131)

Child Pugh Score

8.1 ± 1.6 (66)

8.1 ± 1.4 (62)

8.1 ± 1.5 (128)

Yes

65.2% (45/69)

69.2% (45/65)

67.2% (90/134)

No

34.8% (24/69)

30.8% (20/65)

32.8% (44/134)

Yes

88.4% (61/69)

90.8% (59/65)

89.6% (120/134)

No

11.6% (8/69)

9.2% (6/65)

10.4% (14/134)

CVVH

15.9% (11/69)

22.2% (14/63)

18.9% (25/132)

CVVHD

31.9% (22/69)

27.0% (17/63)

29.5% (39/132)

CVVHDF

52.2% (36/69)

49.2% (31/63)

50.8% (67/132)

Other

0.0% (0/69)

1.6% (1/63)

0.8% (1/132)

BUN (mg/dl)

43.2 ± 25.9 (69)

40.6 ± 29.7 (65)

42.9 ± 27.8 (134)

Creatinine (mg/dl)

2.98 ± 1.65 (69)

2.93 ± 1.70 (65)

2.96 ± 1.6 (134)

Severe Sepsis Status

Ventilator Status

CRRT Modality

doi:10.1371/journal.pone.0132482.t003

secondary endpoint of dialysis dependency. Dialysis dependency (Table 8) showed a borderline
statistically significant difference between the patients maintained for  90% of the treatment
in the protocol’s riCa target range of  0.4 mmol/L over those at  90% of the treatment
Table 4. 60 Day Mortality by Intention to Treat Analysis.
60 Day Mortality

CRRT + SCD

CRRT Alone

Overall

N = 69

N = 65

N = 134

All Subjects Enrolled

100.0% (69/69)

100.0% (65/65)

100.0%(134/134)

Alive

61% (42/69)

64% (38/59*)

63% (80/128)

Dead

39% (27/69)

36% (21/59*)

38% (48/128)

* Does not include six subjects LTFU (002–003, 011–002, 004–007, 011–004, 013–002, 007–025).
doi:10.1371/journal.pone.0132482.t004

PLOS ONE | DOI:10.1371/journal.pone.0132482 August 5, 2015

7 / 13

Clinical Trial of SCD in Acute Kidney Injury

Table 5. Summary of Site-reported Serious Adverse Events (SAEs).
All Subjects N = 132*

Category

Ets

Total

80

Blood and lymphatic system disorders

CRRT + SCD

CRRT Alone

Total

N = 69

N = 63*

N = 132*

Pts

Ets

Pts
% (n/N)

P-Value

65.2% (45/69)

71

63.5% (40/63)

0.857

151

64.4% (85/132)

9

11.6% (8/69)

4

4.8% (3/63)

0.212

13

8.3% (11/132)

Cardiac disorders

15

17.4% (12/69)

11

15.9% (10/63)

1.000

26

16.7% (22/132)

Gastrointestinal disorders

5

5.8% (4/69)

7

9.5% (6/63)

0.518

12

7.6% (10/132)

General disorders and administration site conditions

4

5.8% (4/69)

7

11.1% (7/63)

0.350

11

8.3% (11/132)

Infections and infestations

14

17.4% (12/69)

11

15.9% (10/63)

1.000

25

16.7% (22/132)

% (n/N)

Fisher's Exact

Ets

Pts
% (n/N)

Injury, poisoning and procedural complications

1

1.4% (1/69)

0

0.0% (0/63)

1.000

1

0.8% (1/132)

Investigations

0

0.0% (0/69)

1

1.6% (1/63)

0.477

1

0.8% (1/132)

Metabolism and nutrition disorders

2

2.9% (2/69)

2

3.2% (2/63)

1.000

4

3.0% (4/132)

Musculoskeletal and connective tissue disorders

1

1.4% (1/69)

1

1.6% (1/63)

1.000

2

1.5% (2/132)

Nervous system disorders

6

7.2% (5/69)

1

1.6% (1/63)

0.211

7

4.5% (6/132)

Other

2

2.9% (2/69)

6

7.9% (5/63)

0.258

8

5.3% (7/132)

Psychiatric disorders

0

0.0% (0/69)

1

1.6% (1/63)

0.477

1

0.8% (1/132)

Renal and urinary disorders

1

1.4% (1/69)

3

4.8% (3/63)

0.348

4

3.0% (4/132)

Respiratory, thoracic and mediastinal disorders

13

14.5% (10/69)

10

15.9% (10/63)

1.000

23

15.2% (20/132)

Skin and subcutaneous tissue disorders

0

0.0% (0/69)

2

3.2% (2/63)

0.226

2

1.5% (2/132)

Vascular disorders

7

10.1% (7/69)

4

6.3% (4/63)

0.536

11

8.3% (11/132)

* Two subjects enrolled to CRRT alone arm (012–002, 003–015) however not treated.
doi:10.1371/journal.pone.0132482.t005

duration, 0% (0/16) and 25% (4/16), respectively (Pexact = 010). The association of SCD
treatment with mortality at Day 60 differed significantly by iCa protocol adherence (p-interaction = 0.03), as did the association of treatment with the composite outcome of 60-day mortality or dialysis dependency (p-interaction = 0.004). When the riCa treated and all (intention to
treat) control subgroups were compared for this composite outcome, the percentage of SCD
treated subjects was 16% versus 58% in the control subjects (pexact = 0.01).
Several exploratory biomarkers were evaluated. Neither urine output, elastase, IL-6, and IL10 levels, total white blood cell, neutrophil, and platelet counts throughout treatment differed
in the entire 134 subject cohort. When the recommended ionized calcium (riCa) subpopulation
was considered, a statistically significant difference was detected in several parameters: log
urine output substantially increased (S4 Fig), white blood cell count (WBC) and neutrophil

Table 6. 60 Day Mortality of Subjects–Recommended Ionized Calcium Range (riCa).
60 Day Mortality

CRRT + SCD

CRRT Alone

Overall

riCa

N = 19

N = 27*

N = 46

Alive

84% (16/19)

59% (16/27)

70% (32/46)

Dead

16% (3/19)

41% (11/27)

30% (14/46)

* Three subjects LTFU.
doi:10.1371/journal.pone.0132482.t006
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Table 7. Baseline characteristics of the riCa and non-riCa vs. control subset of patients.
Potential confounding variable

CRRT Alone

CRRT + SCD

riCa SCD

Non-riCa SCD

N = 57

N = 69

N = 19

N = 50

Age (mean)

54.4 ±14.7

58.2 ± 13.0

57.2 ±13.7

58.5 ± 12.8

% Female

38.4

39.1

31.6

42.0

% White

73.8

76.8

89.5

67.9

% Severe Sepsis

69.2

65.2

68.4

64.0

SOFA (mean)

11.8 ±4.1

12.7 ± 4.1

12.0 ±4.1

12.9 ± 4.1

doi:10.1371/journal.pone.0132482.t007

count diminished (S5 and S6 Figs), and elastase increased (S7 Fig) in the treatment vs. control
group over time.

Discussion
Inflammation plays a key role in acute and chronic organ dysfunction [9–11]. Acute organ dysfunction, including AKI, acute lung injury, acute myocardial infarction, and stroke is well correlated to the degree of inflammation. In this study we evaluated the safety and efficacy of a
novel approach to the treatment of kidney failure developing from excessive dysregulated
inflammation. A selective cytopheretic device, which immunomodulates activated circulating
leukocytes in the presence of a citrate induced hypocalcemic environment within an extracorporeal blood circuit, including neutrophils and monocytes was compared to standard of care
therapy with CRRT alone.
To understand the mechanism of action of this device on a profoundly difficult clinical disorder, a series of investigations were performed. Since AKI results in an acute inflammatory
response state resulting in microvascular dysfunction in multiple organs [15], immunoflourescence microscopy of the SCD demonstrated adherent leukocytes on the outer surface of the
membranes of the cartridge along the blood flow path within the extracorporeal circuit [13]. The
sequestered leukocytes were dominated with neutrophils. (S8 Fig) The ability of leukocytes to
bind to the outer walls of the hollow fiber membranes rather than the inner walls, which is the
conventional blood flow path, was recognized to be due to the shear forces of blood flow. The
sheer stress (SS) of blood along the outer wall of the membrane was near capillary SS of <1 dyne/
cm2 compared to the SS of nearly 100 dyne/cm2 of blood when flowing along the inner conventional surfaces of the hollow fiber membranes. The role of citrate infusion in this device blood circuit is related to the effect of citrate to lower the ionized calcium (iCa) levels of blood to below
04mM, a level which inhibits the coagulation system of blood. This lower blood iCa also has an
inhibitory effect on neutrophil activation [13], resulting in a simultaneously combination effect
to sequester activated circulating leukocytes and alter the activity of the bound leukocytes. Further studies now suggest that the bound leukocytes were subsequently released back to the systemic circulation in a less inflammatory state [16]. Consequently, the membrane cartridge is
referred to as a selective cytopheretic device (SCD) and in the presence of citrate anticoagulation,
an immunomodulatory membrane device.
Table 8. Mortality or Dialysis Dependency at Day 60 –Recommended Ionized Calcium Range.
Mortality or Dialysis Dependency at Day 60 –Recommended Ionized
Calcium Range

CRRT + SCD

CRRT
Alone

N

3 / 19

15 / 26

pexact

0.01

doi:10.1371/journal.pone.0132482.t008
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This clinical observation was previously evaluated using the SCD with citrate anticoagulation in a well-established porcine model of E. coli induced septic shock [12]. These studies
demonstrated an ability of the SCD with citrate to lower systemic neutrophil activation, diminish aggregation of activated leukocytes in the lungs, decrease systemic capillary leak, preserve
cardiac output (CO), ameliorate renal dysfunction and prolong survival time compared to various control groups [17]. Further experiments have suggested that the “catch and release” of
activated neutrophils within the SCD promoted the activated neutrophil, which is in a delayed
apoptotic state and has a longer life span, to revert back to a normal time to apoptosis and a
normal life span despite the presence of a SIRS state. This observation is consistent with previous work that suggests that blocking calcium entry into a neutrophil activates the apoptotic
pathway to programmed cell death [18].
The amount of time the subjects in both the control and treatment group were maintained
in the recommended ionized calcium range (025–040 mmol/L), as specified in the study protocol, was substantially lower than expected. One reason for the deficiency in clinical trial execution to ensure the protocol’s riCa target range of  040 mmol/L is maintained could be
attributed to the national shortage of injectable calcium. If the patient did not experience circuit
clotting, the primary investigators’ emphasis of achieving and continuously maintaining the
patient in the recommended ionized calcium range was not consistently adhered to. In addition, the injectable calcium shortage resulted in 9 of the 21 open clinical sites unable to enroll
subjects due to low hospital inventories of injectable calcium. As a result, the study was terminated. The results of this study will be used to design a new clinical trial protocol intended to
achieve a statistically significant difference in SCD therapy vs. CRRT alone on a death or dialysis dependence composite endpoint at 60 days in the treatment of AKI in the setting of critical
illness.
The early termination of the study is a major limitation, but one that leads to a critical conclusion: that the SCD and a calcium concentration of <040 mmol/L are both necessary conditions for immunomodulation. The observation that, in those patients who had the prescribed
iCa level >90% of the time on SCD, mortality improved from 41% to 16%, is clinically compelling. In addition, the observation, both in the pilot Phase II SCD trial [14], and the Phase IIIa
study reported here, that no patient receiving appropriate SCD therapy was dialysis dependent
at Day 60 is also compelling. Previous large prospective clinical studies in AKI with multiorgan
dysfunction had a greater than 20% incidence of dialysis dependency of patients followed for
60 or more days [18, 19]. A sensitivity analysis for riCa in the targeted range was performed for
80%, 85%, and 90% of the treatment time. The mortality effect on SCD-treated patients was
not observed when riCa treatment time was below 90% of that which was prescribed (data not
shown).
Leukocytes play a key role in reperfusion injury after AKI [20–22], and the effect of the SCD
to modulate excessive leukocyte activation most likely plays a critical role in the recovery of
renal function after a substantive AKI event. The relationship of ongoing inflammation in the
kidney after AKI and chronic progressive kidney disease and dialysis dependency has been
demonstrated previously, and may explain the observation in this study that dialysis dependency was decreased for the SCD treated group [23, 24]. Furthermore, the significant divergence of serum elastase levels, as a specific neutrophil activity biomarker between the treated
and control groups is also noteworthy. SCD therapy appears to maintain neutrophil activity
late in the SIRS process compared to the compensatory anti-inflammatory response which
follows the excessive systemic proinflammatory state in AKI and MOD [25]. Thus, the significant decrease in WBC and neutrophil counts, the difference in elastase, the rates of dialysis
dependence, as well as the improvement in urine output over time corroborates the mechanistic role of leukocytes and inflammation on AKI previously published [12–15, 26]. The precise
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mechanism of action is being investigated with data suggesting a role of normalizing the delay
in neutrophil apoptosis promoted by systemic inflammation.
Based on the results described above, one may ask: Is the trend toward improved survival
in the target calcium group the result of low calcium alone or the SCD device, or both. In a
post hoc analysis there was no difference between controls with calcium levels < .04 and controls with calcium levels > .04., suggesting that calcium level alone in the hemofilter is not a
sufficient condition for a survival advantage (S9 Fig) (log-rank p-value = 0.85). In a post
hoc analysis we also compared subjects treated with the SCD who achieved calcium levels
< .04 with those treated with the SCD who achieved calcium levels > .04 (S9 Fig) (log-rank pvalue = 0.03). This revealed a significant mortality benefit, suggesting that low ionized calcium
in the presence of the SCD is a necessary and sufficient condition for better outcomes.

Conclusion
ITT analysis did not demonstrate efficacy of the SCD with 60 day all cause mortality. Intra
SCD calcium levels exceeding 0.4 mm/L were demonstrated in the majority of sites. Circuit
ionized Ca++ levels < 0.4 mm/L alone did not alter 60 day all-cause mortality rates. Circuit Ca
++ levels < 0.4 mm/L in combination with the SCD reduced 60 day all-cause mortality from
40.8% to 15.8% in a post-hoc analysis. While there is no evidence that SCD used in combination with CRRT improves patient survival currently, further studies examining the SCD device
in more regulated perfusion circuit calcium environments are warranted.
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S1 Fig. Schematic of SCD in the CRRT circuit.
(TIF)
S2 Fig. Kaplan-Meier analysis of mortality at Day 60 for 134 patients by ITT analysis (logrank p-value = 023).
(TIF)
S3 Fig. Kaplan-Meier analysis of mortality at Day 60 for those patients who received
the recommended iCa dose >90% of the time when treated with the SCD (log-rank pvalue = 027).
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S4 Fig. Urine output of treated vs. control groups for those patients who received the recommended iCa dose of >90% of the time when treated with the SCD.
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S8 Fig. Kaplan-Meier curve of mortality at Day 60 of riCa and non-riCa subgroups in the
Control patients (log-rank p-value = 0.85).
(TIF)
S9 Fig. Kaplan-Meier analysis of mortality at Day 60 for riCa and non-riCa subgroups in
the SCD treated patients (log-rank p-value = 0.03).
(TIF)
S1 Protocol. SCD-003_protocol_v1.4.
(PDF)
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